Company news

Soligenix, Inc. news in 2026

Soligenix, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

June 8, 2026

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

May 26, 2026

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

April 27, 2026

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

April 1, 2026

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

March 30, 2026

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

March 25, 2026

Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting

March 24, 2026

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

March 22, 2026

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

March 18, 2026

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

March 9, 2026

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

February 26, 2026

Soligenix to Present at BIO Investment & Growth Summit

February 24, 2026

Soligenix Details Recent Progress and Upcoming Milestones

February 12, 2026

Decks in 2026